Drug
89Zr-bevacizumab
89Zr-bevacizumab is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (50.0%)
N/A1 (50.0%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedearly_phase_1
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
NCT01894451
unknownnot_applicable
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT01859234
completed
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
NCT01338090
Clinical Trials (3)
Showing 3 of 3 trials
NCT01894451Early Phase 1
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
NCT01859234Not Applicable
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT01338090
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3